The FDA has accepted for review the resubmitted NDA for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease.

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

The global photodynamic therapy (PDT) devices market is set to witness a growth rate of 9% in the next 5 years. Rising ...

You’ve supercharged your research process with ACS and Mendeley! Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to ...